Sign In
Buy SILO
$5.70
-2.03 (-26.26%)
At Close: Jul 10, 2026
Silo Pharma Announces up to $11.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules
08:00am, Friday, 10'th Jul 2026
$4 million upfront with up to approximately $7.7 million of potential additional gross proceeds upon the exercise in full of warrants in cash
Certara, Silo Pharma Advance AI Agent Strategies with Nvidia Initiatives
02:18pm, Tuesday, 07'th Jul 2026
NVIDIA Corp. (NASDAQ:NVDA) expanded its presence in life sciences AI through separate initiatives with Certara Inc. (NASDAQ:CERT) and Silo Pharma Inc. (NASDAQ:SILO).
Silo Pharma Subsidiary QwikAgents Set to Advance Enterprise AI Agent Platform through NVIDIA Developer Program
08:11am, Tuesday, 07'th Jul 2026
NVIDIA developer program resources expected to support autonomous AI agent innovation and marketing NVIDIA developer program resources expected to support autonomous AI agent innovation and marketing
Silo Pharma Advances SPC-15 PTSD Therapeutic with Drug-Device Robustness Study Ahead of Planned FDA Type C Meeting Request
04:15pm, Monday, 29'th Jun 2026
Study designed to evaluate performance and formulation stability of proprietary nose-to-brain delivery system
Silo Pharma Reports Positive Stability Data for SPC-15 PTSD Treatment, Advancing Program Toward First-in-Human Clinical Trial
08:17am, Tuesday, 23'rd Jun 2026
Positive data supports the continued advancement of FDA Investigational New Drug (IND)- enabling development program SARASOTA, FLA. , June 23, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) ("Sil
Silo Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
08:12am, Thursday, 18'th Jun 2026
SARASOTA, FLA., June 18, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) (“Silo” or “the Company”), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug d
Silo Pharma Files Provisional Patent for Ibogaine-Based Therapeutic Targeting Traumatic Brain Injury
08:05am, Thursday, 07'th May 2026
New initiative from Silo Pharma designed to align with federal actions to accelerate mental health innovation using psychedelic medicines
Silo Pharma's PTSD Program Advances as FDA Fast-Tracks Psychedelic Therapies for PTSD
09:08am, Wednesday, 29'th Apr 2026
Federal initiatives focused on PTSD and related conditions appears to validate need for new and novel approaches to mental health treatment
Silo Pharma’s PTSD Program Advances as FDA Fast-Tracks Psychedelic Therapies for PTSD
09:08am, Wednesday, 29'th Apr 2026
Federal initiatives focused on PTSD and related conditions appears to validate need for new and novel approaches to mental health treatment SARASOTA, Fla, April 29, 2026 (GLOBE NEWSWIRE) -- Silo Pharm
Silo Pharma, Inc. (NASDAQ:SILO) Short Interest Update
05:38am, Monday, 27'th Apr 2026
Silo Pharma, Inc. (NASDAQ: SILO - Get Free Report) was the target of a significant growth in short interest during the month of April. As of April 15th, there was short interest totaling 522,541 share
Launch of Dedicated AI Subsidiary Positions Company for New Revenue Streams While Advancing PTSD Program Toward Phase 1 SARASOTA, FL, April 22, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO
SPC-15 Intranasal PTSD Program Aligns with Federal Push to Fast-Track Novel Mental Health Therapies SARASOTA, Fla. , April 20, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ: SILO), a developmenta
Silo Pharma Rallies After Securing Key Patent Allowance
09:40am, Tuesday, 07'th Apr 2026
Silo said the European Patent Office issued a Rule 71(3) communication indicating its intent to grant a patent for the application, which the company has an exclusive license from Columbia University.
Meanwhile, Iran has submitted a 10-point response to the U.S. peace proposals, which a U.S. official described as "maximalist", citing the Iranian state news agency IRNA.
Silo Pharma (SILO) Stock Soars 47% After European Patent Win: What You Should Know
02:11am, Tuesday, 07'th Apr 2026
Silo Pharma stock jumps after-hours after European patent allowance for PTSD prevention therapy targeting 5-HT4 pathway.
